Accumulation of low-dose BIX01294 promotes metastatic potential of U251 glioblastoma cells

Min Young Kim, Shin-Ji Park, Jae Woong Shim, Yu Song, Kwangmo Yang, Seong‐Joon Park, Kyu HeoOncology 2017 · DOI

Abstract

BIX01294 (Bix) is a known euchromatic histone-lysine N-methyltransferase 2 inhibitor, typically used to suppress cancer cell survival. However, this study reveals that sequential treatment with low-dose Bix notably increases glioblastoma cell migration and metastasis. U251 cells treated sequentially with low-dose Bix exhibited characteristic changes in critical epithelial-mesenchymal transition (EMT) markers and increased expression of cancer stem cell-associated markers (SOX2, OCT4, CD133). These findings suggest that chronic exposure to sub-lethal doses of Bix enhances the invasive potential of glioblastoma by regulating EMT-associated gene expression and altering stem cell properties.

Introduction

Glioblastoma multiforme (GBM) remains one of the most lethal and difficult-to-treat primary brain tumors due to its highly infiltrative nature. While therapeutic strategies often focus on inducing cell death, the epigenetic landscape of these tumors offers complex challenges. BIX01294 (Bix) is a small molecule inhibitor of G9a, an enzyme that methylates histone H3 lysine 9 (H3K9), a modification associated with gene silencing. While high doses of Bix are cytotoxic, the effects of persistent, low-level exposure—common in regions of poor drug penetration—are less understood.

Methods and Experimental Design

The study utilized the U251 human glioblastoma cell line to compare two distinct treatment protocols:

  1. Single Treatment (SBT): Cells received a one-time dose of Bix ranging from 1 to 10 µM.
  2. Sequential Treatment (SeBT): Cells were treated with a low dose (1 µM) of Bix every two days over a 14-day period to simulate chronic accumulation.
Experimental design and the impact of BIX01294 on cell survival and initial molecular markers.

Researchers evaluated cell viability, migration, invasion, and "stemness" through transwell assays and neurosphere formation tests. Molecular changes were tracked using RT-qPCR and Western blotting for EMT and stem cell markers.

Key Results

The Dosage Paradox: Survival vs. Transformation

While higher doses of Bix in the SBT group significantly reduced cell survival and induced markers of apoptosis and autophagy (such as cleaved PARP1 and LC3B-II), the sequential low-dose treatment (SeBT) had negligible effects on cell viability. Instead, SeBT induced a profound phenotypic shift.

Activation of the EMT Program

The most striking finding was the induction of the epithelial-mesenchymal transition (EMT) in SeBT cells. Western blot analysis showed a significant decrease in the epithelial marker E-cadherin, coupled with a marked increase in mesenchymal markers, including N-cadherin, β-catenin, and the transcription factor Slug.

Western blot analysis of EMT-associated markers showing the transition from epithelial to mesenchymal phenotypes in SeBT cells.

Enhanced Migration and Stemness

Functionally, SeBT cells exhibited a 12-fold increase in migratory capacity and a 2.5-fold increase in invasive potential. Furthermore, these cells showed upregulated expression of stem cell markers SOX2, OCT4, and CD133, and demonstrated a significantly higher capacity for neurosphere formation ($P=0.011$). In vivo experiments confirmed these findings, as SeBT-treated cells formed more extensive lung metastases in nude mice compared to controls.

Discussion

The study highlights a "double-edged sword" effect of G9a inhibition. While Bix is a potent anti-cancer agent at therapeutic concentrations, chronic exposure to sub-lethal doses can inadvertently promote a more aggressive, metastatic phenotype. Interestingly, the EMT induction did not strictly correlate with H3K9 methylation levels, suggesting that Bix may influence metastasis through pathways independent of its primary epigenetic target. These results underscore the importance of maintaining consistent drug levels within the tumor microenvironment to avoid unintended promotion of cancer progression.

Summary updated

Abstract

BIX01294 (Bix) is known to be a euchromatic histone-lysine N-methyltransferase 2 inhibitor and treatment with Bix suppresses cancer cell survival and proliferation. In the present study, it was observed that sequential treatment with low-dose Bix notably increases glioblastoma cell migration and metastasis. It was demonstrated that U251 cells sequentially treated with low-dose Bix exhibited induced characteristic changes in critical epithelial-mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, β-catenin and zinc finger protein SNAI2. Notably, sequential treatment with Bix also increased the expression of cancer stem cell-associated markers, including sex determining region Y-box 2, octamer-binding transcription factor 4 and cluster of differentiation 133. Neurosphere formation was significantly enhanced in cells sequentially treated with Bix, compared with control cells (control: P=0.011; single treatment of Bix, P=0.045). The results of the present study suggest that accumulation of low-dose Bix enhanced the migration and metastatic potential of glioblastoma cells by regulating EMT-associated gene expression, which may be the cause of the altered properties of glioblastoma stem cells.
BibTeX
@inproceedings{kim2017accumulation,
  author = {Min Young Kim and Shin-Ji Park and Jae Woong Shim and Yu Song and Kwangmo Yang and Seong‐Joon Park and Kyu Heo},
  title = {{Accumulation of low-dose BIX01294 promotes metastatic potential of U251 glioblastoma cells}},
  booktitle = {Oncology},
  year = {2017},
  doi = {10.3892/ol.2017.5626},
}
Figure